Confidential Treatment Requested Under 17 C.F.R. 200.80(b)(4) and 240.24b-2
Exhibit 10.48
| Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and |
|
CHANGE ORDER
AMENDED LETTER OF PAYMENT AUTHORIZATION
Amendment No. 01
September 10, 2012
Gary Hattersley, Ph.D.
Vice President, Biology
RADIUS HEALTH, INC.
6th Floor
201 Broadway
Cambridge, MA 02139
United States
***@***
| RE: | STUDY PN 670646 | Study Title: A 12-Month Osteoporosis Intervention Study BA058 by Subcutaneous Injection in the Ovariectomized Sprague Dawley Rats |
|
|
|
|
|
| As per Protocol Amendment # 1 dated: April 28, 2011 As per Protocol Amendment # 2 dated: July 26, 2011 As per Protocol Amendment # 4 dated: October 20, 2012 As per Protocol Amendment # 6 dated: July 26, 2012 | |
|
|
| |
|
| STUDY START: May 2011 | |
Dear Gary,
This communication is to serve as an Amended Letter of Payment Authorization (ALOPA) for the above referenced study, which will be performed at Charles River Laboratories Preclinical Services as set forth below. Charles River Laboratories Preclinical Services shall perform these services in accordance with the existing Service Agreement executed between Charles River Laboratories Preclinical Services and RADIUS HEALTH, INC. Once fully executed, this ALOPA shall be incorporated into and made part of the existing Service Agreement.
Summary of Changes:
·Slide preparation and evaluation
·Statistics added
The price of this Protocol Amendment is as follows:
|
| Authorized Price |
| $ [*] |
|
| (after discount) |
| (as per signed ALOPA dated: February 1, 2011) |
|
|
|
|
|
|
| Additional Charge |
| $ [*] |
|
|
|
|
|
|
| Additional Charge: |
|
|
|
| (with [*]% + [*]% discounts) |
| $ [*] |
|
|
|
|
|
|
| Revised Price |
| $ 1,081,896 US |
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
1
The payment schedules of this study are as follows:
·$ [*] [15%] Due at animal arrival — (Paid)
·$ [*] [75%] Equal Monthly Installment — (Invoiced and paid)
·$ [*] Additional Charge Due upon receipt of invoice — (ALOPA1)
·$ [*] [75%] Equal Monthly Installment
·$ [*] [5%] Due upon Submission of Draft Report
·$ [*] [5%] Due upon Submission of Final Report
Please sign and return this document via facsimile or email (contact information below). Should you have any questions or require any additional information, please do not hesitate to call me. We look forward to being of service.
Best regards,
| /s/ Stéphane Besner |
| /s/ Gary Hattersley |
|
|
| Authorized Sponsor Representative |
| Stéphane Besner, B.Sc. M.B.A |
|
|
| Senior Client Manager, Sales & Marketing |
| Gary Hattersley, SVP Preclinical Development |
| Charles River Laboratoires |
| Print (Name and Title) |
| Preclinical Services Montreal Inc. |
|
|
| 22022 Transcanadienne |
| September 14, 2012 |
| Senneville, Québec, Canada H9X 3R3 |
| Date |
| Tel: (514) 630-2436 Fax: (514) 630-8230 |
|
|
| e-mail ***@*** |
|
|
| Web site: www.criver.com |
|
|
If a PO is required, please submit PO with Letter of Payment Authorization or fax to ###-###-####.
c.c. S. Pryce, D. Tremblay, S Y. Smith, E. Lesage
CRT: 24056
E:\CLIENTS\Radius\2012\670646.L7(ALOPA1) 10Sep12.doc
O6UJ9 - A0013JF
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
2
